FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563738770> ?p ?o ?g. }

• W2563738770 abstract "Abstract Introduction: The standard first-line treatment for patients with multiple myeloma (MM) has been melphalan plus prednisone (MP). However, complete responses (CRs) are rare. As single agents, bortezomib (V) and thalidomide (T) achieved responses in &lt;50% of newly diagnosed MM patients, whereas combinations of V or T with dexamethasone (D), designated VD and TD, demonstrated response rates of 85% and 63%, respectively. We examined the anti-MM activity and neurotoxicity of VT, a steroid-free regimen. Methods: In this phase II study in 30 untreated MM patients, bortezomib 1.3mg/m2 was administered intravenously on days 1, 4, 8, and 11 of a 21-day cycle for up to 8 cycles. Thalidomide 100mg was administered orally at bedtime on days 1 through 21 for up to 8 cycles. Response was assessed with European Group for Blood and Marrow Transplantation (EBMT) criteria. Newly diagnosed MM patients (including Phase IB, II and III according to the International Myeloma Working Group [IMWG] criteria) were eligible if they were 18–80 years of age, had anticipated life expectancy &gt;6 months, and had an age-adjusted creatinine clearance of ≥15 mL/min within 14 days before enrollment. Results: Median age was 56.6 years (range, 30–77), albumin was &lt;3.5g/dL in 18 patients (60%), b2-microglobulin was ≥3.5mg/L in 20 patients (66%), and hemoglobin was ≥100g/L only in 9 patients (30%). International Staging System I/II/III were 3%/50%/47% respectively; all patients had stage III MM according to the IMWG criteria. There were 26 patients (87%) who completed at least two cycles of therapy and were evaluable for response; 18 (60%) completed the planned 8 cycles. Treatment was discontinued in 4 patients due to renal failure. Rates of overall response (ORR), CR, near CR (nCR), partial response (PR), and stable disease (SD) are summarized in Table 1. Median time to response was 35.6 days (range, 7–60). The best response occurred within the first 4 cycles in 96% of patients. Side effects were predictable and manageable. The main toxicities were hematologic (53%), fever (47%), gastrointestinal (40%), fatigue (37%), and peripheral neuropathy (36%). Grade 3 nonhematologic adverse events included 4 patients (15%) with renal failure associated with tumor lysis syndrome, 1 patient (4%) with peripheral sensory neuropathy and motor neuropathy that improved with VT dose reductions, and 1 patient (4%) with hypotension. One patient (4%) experienced Grade 4 thrombocytopenia. One patient (4%) died due to acute renal failure. No deep vein thromboses occurred in this study, compared with a reported incidence of thromboembolic events between 15–20% with TD-containing regimens. Conclusions: VT produced very high ORR and CR in the treatment of newly diagnosed MM patients. No DVTs occurred with this steroid-free combination without any use of anticoagulant drugs. The rate of peripheral neuropathy was lower than expected. This is a very effective regimen with manageable toxicity. Table 1. Response of Newly Diagnosed MM to Bortezomib 1.3mg/m2 and Thalidomide 100mg completed cycles N ORR n (%) CR n (%) nCR n (%) PR n (%) SD n (%) 2 cycles 26 25 (96) 12 (46) 4 (15) 9 (35) 1 (4) 4 cycles 21 20 (95) 6 (29) 7 (33) 7 (33) 0 (0) 8 cycles 18 16 (89) 5 (28) 4 (22) 7 (39) 2 (11)" @default.
• W2563738770 created "2017-01-06" @default.
• W2563738770 creator A5001443657 @default.
• W2563738770 creator A5016322565 @default.
• W2563738770 creator A5017804632 @default.
• W2563738770 creator A5086531001 @default.
• W2563738770 creator A5088688923 @default.
• W2563738770 creator A5091598527 @default.
• W2563738770 date "2007-11-16" @default.
• W2563738770 modified "2023-09-28" @default.
• W2563738770 title "Bortezomib Plus Thalidomide Treatment of Newly Diagnosed Patients with Multiple Myeloma - Efficacy and Neurotoxicity: Results of a Multicenter Study." @default.
• W2563738770 doi "https://doi.org/10.1182/blood.v110.11.3600.3600" @default.
• W2563738770 hasPublicationYear "2007" @default.
• W2563738770 type Work @default.
• W2563738770 sameAs 2563738770 @default.
• W2563738770 citedByCount "3" @default.
• W2563738770 crossrefType "journal-article" @default.
• W2563738770 hasAuthorship W2563738770A5001443657 @default.
• W2563738770 hasAuthorship W2563738770A5016322565 @default.
• W2563738770 hasAuthorship W2563738770A5017804632 @default.
• W2563738770 hasAuthorship W2563738770A5086531001 @default.
• W2563738770 hasAuthorship W2563738770A5088688923 @default.
• W2563738770 hasAuthorship W2563738770A5091598527 @default.
• W2563738770 hasConcept C126322002 @default.
• W2563738770 hasConcept C126894567 @default.
• W2563738770 hasConcept C141071460 @default.
• W2563738770 hasConcept C2776364478 @default.
• W2563738770 hasConcept C2777478702 @default.
• W2563738770 hasConcept C2778684742 @default.
• W2563738770 hasConcept C2778720950 @default.
• W2563738770 hasConcept C2779609412 @default.
• W2563738770 hasConcept C2780306776 @default.
• W2563738770 hasConcept C2781413609 @default.
• W2563738770 hasConcept C2911091166 @default.
• W2563738770 hasConcept C71924100 @default.
• W2563738770 hasConcept C90924648 @default.
• W2563738770 hasConceptScore W2563738770C126322002 @default.
• W2563738770 hasConceptScore W2563738770C126894567 @default.
• W2563738770 hasConceptScore W2563738770C141071460 @default.
• W2563738770 hasConceptScore W2563738770C2776364478 @default.
• W2563738770 hasConceptScore W2563738770C2777478702 @default.
• W2563738770 hasConceptScore W2563738770C2778684742 @default.
• W2563738770 hasConceptScore W2563738770C2778720950 @default.
• W2563738770 hasConceptScore W2563738770C2779609412 @default.
• W2563738770 hasConceptScore W2563738770C2780306776 @default.
• W2563738770 hasConceptScore W2563738770C2781413609 @default.
• W2563738770 hasConceptScore W2563738770C2911091166 @default.
• W2563738770 hasConceptScore W2563738770C71924100 @default.
• W2563738770 hasConceptScore W2563738770C90924648 @default.
• W2563738770 hasLocation W25637387701 @default.
• W2563738770 hasOpenAccess W2563738770 @default.
• W2563738770 hasPrimaryLocation W25637387701 @default.
• W2563738770 hasRelatedWork W1964991829 @default.
• W2563738770 hasRelatedWork W2025081120 @default.
• W2563738770 hasRelatedWork W2034642132 @default.
• W2563738770 hasRelatedWork W2112489854 @default.
• W2563738770 hasRelatedWork W2116032799 @default.
• W2563738770 hasRelatedWork W2154021003 @default.
• W2563738770 hasRelatedWork W2348551523 @default.
• W2563738770 hasRelatedWork W2364383807 @default.
• W2563738770 hasRelatedWork W2795418276 @default.
• W2563738770 hasRelatedWork W2957896353 @default.
• W2563738770 isParatext "false" @default.
• W2563738770 isRetracted "false" @default.
• W2563738770 magId "2563738770" @default.
• W2563738770 workType "article" @default.